Discrepancies in Care Identified in Chart Review for Adherence to Recommendations
| Discrepancy | Proportion (%) |
|---|---|
| Corrected gender marker/name | 11/65 (16.9) |
| Recommended PrEP | 1/65 (1.3) |
| Contraception/family planning recommended | 3/65 (4.6) |
| Needed updated mental health screen | 27 (41.5) |
| Health maintenance: Papanicolaou smear needed | 9/16 (56.3) |
| Health maintenance: mammogram needed | 2/3 (66.7) |
| Health maintenance: DEXA needed | 1/2 (50.0) |
| Needed to be scheduled for follow-up | 40 (61.5) |
| Gender-affirming hormone therapy | |
| Testosterone: CI identified | 0/22 (0) |
| Testosterone: laboratory tests needed | 15/22 (68.2) |
| Estradiol: CI identified | 1/15 (6.7) |
| Estradiol: laboratory tests needed | 4/15 (26.7) |
| Androgen blocker: CI identified | 0/14 (0) |
| Androgen blocker: laboratory tests needed | 8/14 (57.1) |
Abbreviations: CI, contraindication; DEXA, dual-energy radiograph absorptiometry; PrEP, pre-exposure prophylaxis.